Pfizer raises COVID-19 sales forecast to $33.5 billion for 2021
Pfizer raised its 2021 sales forecast for the vaccine from $26 billion to $33.5 billion after the pharmaceutical giant sold $7.8 billion in COVID-19 shots in the second quarter. The spread of the delta variant has ignited the debate surrounding booster shots
By
Published - Jul 28, 2021, 06:32 PM ET
Last Updated - Jun 05, 2024, 12:03 AM EDT
By Yashasvini Razdan, 1:00 PM ET
Pfizer raised its 2021 sales forecast for the vaccine from $26 billion to $33.5 billion after the pharmaceutical giant sold $7.8 billion in COVID-19 shots in the second quarter. The spread of the delta variant has ignited the debate surrounding booster shots.
The company based its raised sales forecast of the vaccine on signed deals for 2.1 billion doses. The company could increase its production if it signs additional contracts.
The company’s second-quarter earnings were reported as $1.07 per share beating Wall Street’s expected 97 cents per share. Its reported revenue of $18.98 billion also exceeded the Wall Street forecast of $18.74 billion.
